Skip to main content

Silencing PRDM14 via Oligonucleotide Therapeutics Suppresses Tumorigenicity and Metastasis of Breast Cancer

  • Protocol
  • First Online:
RNA Interference and Cancer Therapy

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1974))

Abstract

The PRDI-BF1 and RIZ (PR) domain zinc finger protein 14 (PRDM14) is upregulated in approximately 60% of breast cancers, some of which exhibit gene amplification. In contrast, PRDM14 is not expressed in normal, and differentiated tissues. PRDM14+ breast cancer cells are resistant to chemotherapy drugs, are tumorigenic, and metastasize to the lungs. It is commonly assumed that genes that are overexpressed in cancers, such as PRDM14, are effective targets for new therapies that specifically abrogate the expression of these genes. RNA interference of PRDM14, a gene expressed by breast cancer cells, reduced the size of tumors and lung metastases in nude mice. In this chapter, we introduce the concept and methods to develop and apply systematically injected small interfering RNA therapy for breast cancer models in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mzoughi S, Tan YX, Low D et al (2016) The role of PRDMs in cancer: one family, two sides. Curr Opin Genet Dev 36:83–91

    Article  CAS  PubMed  Google Scholar 

  2. Yamaji M, Seki Y, Kurimoto K et al (2008) Critical function of Prdm14 for the establishment of the germ cell lineage in mice. Nat Genet 40:1016–1022

    Article  CAS  PubMed  Google Scholar 

  3. Yamaji M, Ueda J, Hayashi K et al (2013) PRDM14 ensures naive pluripotency through dual regulation of signaling and epigenetic pathways in mouse embryonic stem cells. Cell Stem Cell 12:368–382

    Article  CAS  PubMed  Google Scholar 

  4. Nishikawa N, Toyota M, Suzuki H et al (2007) Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 67:9649–9657

    Article  CAS  PubMed  Google Scholar 

  5. Dettman EJ, Justice MJ (2008) The zinc finger SET domain gene Prdm14 is overexpressed in lymphoblastic lymphomas with retroviral insertions at Evi32. PLoS One 3:e3823

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Taniguchi H, Hoshino D, Moriya C et al (2017) Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer. Oncotarget 8:46856–46874

    Article  PubMed  PubMed Central  Google Scholar 

  7. Moriya C, Taniguchi H, Miyata K et al (2017) Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice. Carcinogenesis 38:638–648

    Article  CAS  PubMed  Google Scholar 

  8. Ui-Tei K, Naito Y, Saigo K (2006) Essential notes regarding the design of functional siRNAs for efficient mammalian RNAi. J Biomed Biotechnol 2006:1–8

    Article  Google Scholar 

  9. Naito Y, Yoshimura J, Morishita S et al (2009) siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 10:392

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ui-Tei K, Naito Y, Zenno S et al (2008) Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 36:2136–2151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pittella F, Cabral H, Maeda Y et al (2014) Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. J Control Release 178:18–24

    Article  CAS  PubMed  Google Scholar 

  12. Shimizu H, Hori Y, Kaname S et al (2010) siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol 21:622–633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the Department of Research Promotion, Practical Research for Innovative Cancer Control, Ministry of Health, Labour and Welfare, and the Japan Agency for Medical Research and Development (AMED). We wish to thank Prof. Kazunori Kataoka from the Innovation Center of NanoMedicine for the DDSs and Prof. Yukikazu Natori and Associate professor Kumiko Ui-Tei from the University of Tokyo for chimera siRNA and selection of highly effective siRNA sequences for RNAi. We also would like to thank Editage (www.editage.jp) for English language editing.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroaki Taniguchi .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Taniguchi, H., Imai, K. (2019). Silencing PRDM14 via Oligonucleotide Therapeutics Suppresses Tumorigenicity and Metastasis of Breast Cancer. In: Dinesh Kumar, L. (eds) RNA Interference and Cancer Therapy. Methods in Molecular Biology, vol 1974. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9220-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9220-1_18

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9219-5

  • Online ISBN: 978-1-4939-9220-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics